STOCK TITAN

SOPHiA GENETICS SA (SOPH) Financials

SOPH NASDAQ
FY2025 annual
Revenue $77.3M +18.6% YoY
Net Income -$79.0M n/m YoY
EPS (Diluted) -$1.17 n/m YoY
Free Cash Flow -$36.5M n/m YoY
Market Cap $533.7M as of Nov 20, 2026
Price / Sales 6.9x on $77.3M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 11.3x on $47.1M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SOPH SEC filings page.

SOPHiA GENETICS SA (SOPH) reported $77.3M in revenue for fiscal year 2025, up 18.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI SOPH FY2025

Revenue is expanding with stable gross margins, but rising financing costs and leverage keep losses substantial.

FY2025 revenue grew 18.6% while gross margin held at 67.4%, indicating expansion without better reported economics per sale. Yet operating loss narrowed while net loss widened, alongside a 138.1% increase in interest expense, showing financing costs—not core gross margin—helped pull bottom-line results backward.

Operating cash flow improved from an outflow of $44.5M to $35.9M in FY2025, while free cash flow also remained negative. Capital expenditures were only $574K, so the reduced cash shortfall appears tied mainly to operating losses rather than reinvestment intensity.

The balance sheet moved from lightly debt-financed to materially more leveraged: liabilities reached 71.1% of assets and debt-to-equity reached 1.0x in FY2025. With current ratio at 2.0x and R&D still 44.3% of revenue, the company retains short-term coverage while funding a development-heavy cost base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 63 / 100
Financial Health Score (4 of 6 dimensions) 63/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of SOPHiA GENETICS SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
n/a

Not available for SOPHiA GENETICS SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Dilution
75

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. SOPHiA GENETICS SA scores 75/100 on it among other emerging companies.

R&D Intensity
55

SOPHiA GENETICS SA spent $34.2M on research and development in fiscal year 2025, which was 23.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and SOPHiA GENETICS SA scores 55/100 among other emerging companies.

Revenue Progress
55

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. SOPHiA GENETICS SA scores 55/100 on it among other emerging companies.

Burn Trend
66

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. SOPHiA GENETICS SA scores 66/100 on it among other emerging companies.

Balance Sheet
n/a

Not available for SOPHiA GENETICS SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Altman Z-Score Distress
-2.30

SOPHiA GENETICS SA scores -2.30, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $519.3M against total assets of $163.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak
2/9

SOPHiA GENETICS SA passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

SOPHiA GENETICS SA reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

SOPHiA GENETICS SA reported an operating loss of $70.9M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$77.3M
YoY+18.6%
5Y CAGR+22.2%

SOPHiA GENETICS SA generated $77.3M in revenue in fiscal year 2025. This represents an increase of 18.6% from the prior year.

Net Income
-$79.0M
YoYn/m
5Y CAGRn/m

SOPHiA GENETICS SA reported a net loss of $79.0M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$1.17
YoYn/m
5Y CAGRn/m

SOPHiA GENETICS SA earned -$1.17 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$36.5M
YoYn/m
5Y CAGRn/m

SOPHiA GENETICS SA recorded an outflow of $36.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$70.3M
YoY-12.4%
5Y CAGR-1.2%

SOPHiA GENETICS SA held $70.3M in cash against $47.7M in long-term debt as of fiscal year 2025.

Shares Outstanding
68M
YoY+2.7%

SOPHiA GENETICS SA had 68M shares outstanding in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
67.4%
YoY0.0pp
5Y change+5.1pp

SOPHiA GENETICS SA's gross margin was 67.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.

Operating Margin
-91.8%

SOPHiA GENETICS SA's operating margin was -91.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity
-167.6%
YoY-102.8pp
5Y change-128.4pp

SOPHiA GENETICS SA's ROE was -167.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 102.8 percentage points from the prior year.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$34.2M
YoY-0.4%
5Y CAGR+13.0%

SOPHiA GENETICS SA invested $34.2M in research and development in fiscal year 2025. This represents a decrease of 0.4% from the prior year.

Capital Expenditures
$574K
YoY+135.2%
5Y CAGR+5.0%

SOPHiA GENETICS SA invested $574K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 135.2% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

SOPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Revenue$77.3M+18.6%$65.2M+4.5%$62.4M+31.1%$47.6M+17.6%$40.5M+42.4%$28.4M+12.0%$25.4M
Cost of Revenue$25.2M+18.6%$21.2M+9.1%$19.5M+19.3%$16.3M+7.1%$15.2M+42.2%$10.7M+42.2%$7.5M
Gross Profit$52.1M+18.5%$43.9M+2.4%$42.9M+37.3%$31.3M+23.9%$25.2M+42.6%$17.7M-0.8%$17.8M
R&D Expenses$34.2M-0.4%$34.4M-7.0%$37.0M+4.5%$35.4M+33.1%$26.6M+43.0%$18.6M+23.8%$15.0M
Operating Income-$70.9Mn/m-$66.6Mn/m-$74.8Mn/m-$87.8Mn/m-$71.5Mn/m-$37.4MN/A
Interest Expense$4.6M+138.1%$1.9M+225.3%$588K-8.0%$639K-2.9%$658K-21.7%$840K-13.9%$976K
Income Tax$1.5M+23.6%$1.2M+151.6%$486Kn/m-$136K-181.0%$168Kn/m-$1.9M-1264.2%$162K
Net Income-$79.0Mn/m-$62.5Mn/m-$79.0Mn/m-$87.4Mn/m-$73.7Mn/m-$39.3Mn/m-$33.8M
EPS (Basic)-$1.17n/m-$0.95n/m-$1.22n/m-$1.36n/m-$1.33n/m-$0.93N/A
EPS (Diluted)-$1.17n/m-$0.95n/m-$1.22n/m-$1.36n/m-$1.33n/m-$0.93N/A
Diluted Shares (Avg)68M+2.2%66M+2.0%65M+1.0%64M+15.9%55M+30.6%42MN/A

Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.

SOPH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Total Assets$163.0M+5.0%$155.3M-24.7%$206.2M-15.5%$243.8M-23.8%$320.2M+142.3%$132.1MN/A
Current Assets$99.1M-0.3%$99.4M-32.9%$148.0M-24.6%$196.3M-30.6%$282.9M+157.9%$109.7MN/A
Cash & Equivalents$70.3M-12.4%$80.2M-34.9%$123.3M-23.6%$161.3M-16.4%$193.0M+158.6%$74.6M+313.0%$18.1M
Inventory$6.4M+8.2%$5.9M-9.5%$6.5M+25.7%$5.2M-10.0%$5.7M+69.3%$3.4MN/A
Accounts Receivable$15.0M+101.7%$7.4M-45.2%$13.6M+103.9%$6.6M+5.9%$6.3M-1.3%$6.4MN/A
Goodwill$35.9M+23.8%$29.0M+6.7%$27.2M+36.2%$20.0M+27.4%$15.7M+18.0%$13.3MN/A
Total Liabilities$115.9M+97.0%$58.8M+7.5%$54.7M+25.2%$43.7M-2.4%$44.8M+41.7%$31.6MN/A
Current Liabilities$50.5M+88.5%$26.8M-24.8%$35.6M+32.9%$26.8M-6.3%$28.6M+32.5%$21.6MN/A
Non-Current Liabilities$65.4M+104.1%$32.0M+67.7%$19.1M+13.0%$16.9M+4.5%$16.2M+61.4%$10.0MN/A
Long-Term Debt$47.7M+260.6%$13.2Mn/m$0N/A$0-100.0%$457K-88.1%$3.8M
Total Equity$47.1M-51.1%$96.5M-36.3%$151.4M-24.3%$200.1M-27.3%$275.4M+174.0%$100.5M+351.7%$22.3M
Retained Earnings-$519.3Mn/m-$440.3Mn/m-$377.8Mn/m-$298.8Mn/m-$211.4Mn/m-$137.7MN/A

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

SOPH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Operating Cash Flow-$35.9Mn/m-$44.5Mn/m-$53.2Mn/m-$70.1Mn/m-$57.9Mn/m-$31.7Mn/m-$31.7M
Capital Expenditures$574K+135.2%$244K-83.7%$1.5M-63.5%$4.1M+52.7%$2.7M+496.2%$450K-66.8%$1.4M
Free Cash Flow-$36.5Mn/m-$44.8Mn/m-$54.7Mn/m-$74.2Mn/m-$60.6Mn/m-$32.2Mn/m-$33.0M
Investing Cash Flow-$8.7Mn/m-$4.8M-136.6%$13.0M-69.1%$42.0Mn/m-$56.9Mn/m-$24.3Mn/m-$3.0M
Financing Cash Flow$30.2M+206.1%$9.9Mn/m-$2.8Mn/m-$1.6M-100.7%$237.8M+122.1%$107.0Mn/m-$1.0M

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.

SOPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SOPH annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Gross Margin67.4%0.0pp67.4%-1.4pp68.8%+3.1pp65.7%+3.4pp62.4%+0.1pp62.3%-8.0pp70.3%
Operating Margin-91.8%-102.1%-120.0%-184.7%-176.7%-131.6%N/A
Net Margin-102.2%-95.9%-126.6%-183.9%-182.1%-138.5%-133.2%
Return on Equity-167.6%-102.8pp-64.8%-12.6pp-52.1%-8.4pp-43.7%-16.9pp-26.8%+12.4pp-39.1%+112.7pp-151.8%
Return on Assets-48.5%-8.2pp-40.2%-1.9pp-38.3%-2.5pp-35.9%-12.8pp-23.0%+6.8pp-29.8%N/A
Current Ratio1.96-1.7x3.71-0.4x4.16-3.2x7.32-2.6x9.89+4.8x5.08N/A
Debt-to-Equity1.01+0.9x0.14+0.1x0.00N/A0.000.0x0.00-0.2x0.17
Liabilities-to-Equity2.46+1.8x0.61+0.2x0.36+0.1x0.22+0.1x0.16-0.2x0.31N/A
Asset Turnover0.47+0.1x0.42+0.1x0.30+0.1x0.20+0.1x0.13-0.1x0.22N/A
FCF Margin-47.2%+21.5pp-68.7%+19.1pp-87.7%-156.0%-149.9%-113.3%-130.3%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
SOPHiA GENETICS SA SOPH FY2025 $77.3M -$79.0M N/A $533.7M 63/100
NRC Health NRC FY2025 $137.4M $11.3M 8.2% $533.9M 51/100
Evolent Health, Inc EVH FY2025 $1.9B -$534.5M -28.5% $441.1M 22/100
Phreesia, Inc. PHR FY2026 $480.6M $2.3M 0.5% $708.2M 47/100
Carlsmed, Inc. CARL FY2025 $50.5M -$29.6M -58.7% $477.4M 54/100
HealthStream Inc HSTM FY2025 $304.1M $18.3M 6.0% $804.4M 53/100

Frequently Asked Questions

SOPHiA GENETICS SA (SOPH) reported $77.3M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

SOPHiA GENETICS SA (SOPH) revenue grew by 18.6% year-over-year, from $65.2M to $77.3M in fiscal year 2025.

No, SOPHiA GENETICS SA (SOPH) reported a net loss of $79.0M in fiscal year 2025.

SOPHiA GENETICS SA (SOPH) reported diluted earnings per share of -$1.17 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, SOPHiA GENETICS SA (SOPH) had $70.3M in cash and equivalents against $47.7M in long-term debt.

SOPHiA GENETICS SA (SOPH) had a gross margin of 67.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

SOPHiA GENETICS SA (SOPH) had an operating margin of -91.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

SOPHiA GENETICS SA (SOPH) has a return on equity of -167.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

SOPHiA GENETICS SA (SOPH) recorded an outflow of $36.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

SOPHiA GENETICS SA (SOPH) recorded an outflow of $35.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

SOPHiA GENETICS SA (SOPH) had $163.0M in total assets as of fiscal year 2025, including both current and long-term assets.

SOPHiA GENETICS SA (SOPH) invested $574K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

SOPHiA GENETICS SA (SOPH) invested $34.2M in research and development during fiscal year 2025.

SOPHiA GENETICS SA (SOPH) had 68M shares outstanding as of fiscal year 2025.

SOPHiA GENETICS SA (SOPH) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.

SOPHiA GENETICS SA (SOPH) had a debt-to-equity ratio of 1.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

SOPHiA GENETICS SA (SOPH) had a liabilities-to-equity ratio of 2.46 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

SOPHiA GENETICS SA (SOPH) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

SOPHiA GENETICS SA (SOPH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $533.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

SOPHiA GENETICS SA (SOPH) trades at 6.9x sales, its market capitalization divided by $77.3M revenue, FY2025. The market capitalization is $533.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

SOPHiA GENETICS SA (SOPH) has an Altman Z-Score of -2.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

SOPHiA GENETICS SA (SOPH) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

SOPHiA GENETICS SA (SOPH) reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

SOPHiA GENETICS SA (SOPH) reported an operating loss of $70.9M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

SOPHiA GENETICS SA (SOPH) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For SOPHiA GENETICS SA it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top